Latest Ratios: P/E Ratio -2.0x · EV/EBITDA N/A · ROE -60.3%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $444M | $390M | $1.2B | $2.5B | $1.3B | $1.4B | $3.0B | $1.1B | $584M | $71M | $163M |
| Enterprise Value | $392M | $337M | $1.1B | $2.5B | $1.2B | $1.2B | $2.8B | $978M | $514M | $41M | $182M |
| P/E Ratio → | -2.02 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.63 | 1.41 | 2.57 | 5.11 | 2.72 | 3.04 | 6.03 | 3.63 | 3.01 | 1.48 | 2.23 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | -60.3% | -54.1% | -50.0% | -47.0% | -35.3% | -36.2% | -33.2% | -61.6% | -48.8% | -47.1% |
| ROA | -52.0% | -52.0% | -47.3% | -43.9% | -42.3% | -31.1% | -30.5% | -26.7% | -42.2% | -25.5% | -35.3% |
| ROIC | -62.4% | -62.4% | -52.1% | -46.7% | -54.6% | -48.9% | -46.6% | -38.9% | -74.8% | -36.2% | -51.9% |
| ROCE | -58.1% | -58.1% | -54.4% | -50.4% | -45.4% | -32.4% | -29.8% | -25.8% | -42.7% | -24.3% | -36.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.06 | 0.05 | 0.05 | 0.05 | 0.12 | 0.15 | 0.21 | 1.04 | 0.67 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.30 | -0.06 | -0.24 | -0.46 | -0.47 | -0.45 | -0.36 | -0.61 | 0.26 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -116.99 | -116.99 | -136.19 | -129.98 | -115.22 | -27.71 | -17.59 | -14.96 | -13.11 | -5.65 | -29.22 |
Net cash position: cash ($78M) exceeds total debt ($25M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Quick Ratio | 6.38 | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Cash Ratio | 6.25 | 6.25 | 9.15 | 7.69 | 9.10 | 17.54 | 14.80 | 16.61 | 13.38 | 24.57 | 17.54 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $111M | $95M | $84M | $68M | $63M | $55M | $49M | $39M | $7M | $7M |
Capital runway and dilution
As reported in financial statements, Rocket Pharmaceuticals has consistently generated negative ROIC, with figures hovering around -16.6% in 2026Q1, reflecting the structural inability of a pre-revenue biotechnology firm to generate returns on invested capital while simultaneously funding intensive, multi-year clinical development programs for its gene therapy pipeline.
The persistent negative ROIC trend suggests that the company is currently in a value-consuming phase, which is typical for the industry but warrants caution regarding the efficiency of capital deployment. Investors should monitor whether the transition to commercialization can eventually pivot these metrics toward positive territory as clinical milestones are achieved.
Based on RCKT's reported figures, the current ratio has compressed from 10.47 in 2024Q1 to 6.12 in 2026Q1, indicating that while the company maintains a high level of short-term liquidity, the rapid depletion of cash reserves relative to ongoing R&D burn rates suggests a tightening operational runway.
The decline in the current ratio appears to be a direct consequence of the company's aggressive clinical trial schedule and the associated cash outflows. While the current liquidity position remains adequate for the immediate term, the downward trajectory suggests that the company may face significant financing requirements before reaching commercial self-sufficiency.
According to recent SEC filings, Rocket Pharmaceuticals maintains a low debt-to-equity ratio of 0.10 as of 2026Q1, which suggests that management has successfully avoided reliance on debt financing to fund its operations, opting instead to preserve balance sheet flexibility during this high-risk, pre-revenue development phase.
The minimal leverage profile is appropriate given the lack of predictable cash flows to service interest obligations. However, the company's reliance on equity-based financing to maintain this low leverage may lead to significant shareholder dilution, a factor that investors should weigh against the benefits of a debt-free balance sheet.
As indicated by the company's financial data, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to RCKT, as these metrics obscure the value of the company's clinical-stage pipeline and the potential for non-dilutive capital generation through Priority Review Vouchers upon successful regulatory approval.
Analysts should instead focus on 'burn-to-milestone' ratios and the net present value of the company's lead assets, as traditional earnings-based multiples fail to capture the binary nature of gene therapy development. Relying on P/E ratios in this context may lead to an erroneous conclusion that the company is undervalued, when in reality, the valuation is entirely dependent on clinical success and regulatory outcomes.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RCKT stock.
Rocket Pharmaceuticals, Inc.'s current P/E ratio is -2.0x. This places it at the 50th percentile of its historical range.
Rocket Pharmaceuticals, Inc.'s return on equity (ROE) is -60.3%. The historical average is -64.6%.
Based on historical data, Rocket Pharmaceuticals, Inc. is trading at a P/E of -2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.